Pernix Therapeutics Reports Second Quarter 2010 Results
Posted on 08/16/2010
MAGNOLIA, Texas, August 16, 2010 – Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company primarily focused on the pediatric market, today announced results for the quarter and six months ended June 30, 2010.
» Continue Reading Pernix Therapeutics Reports Second Quarter 2010 Results
Pernix Therapeutics To Report Second Quarter 2010 Results On August 16, 2010
Posted on 08/12/2010
MAGNOLIA, Texas, August 12, 2010 – Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX) today announced that it will release its second quarter 2010 financial results following the close of the market on Monday, August 16, 2010, and will host a conference call to discuss the results and provide a general business update at 11:00 AM EDT on Wednesday, August 18, 2010.
» Continue Reading Pernix Therapeutics To Report Second Quarter 2010 Results On August 16, 2010
Pernix Therapeutics Holdings, Inc. Announces Stock Repurchase Authorization
Posted on 05/19/2010
MAGNOLIA, Texas--(BUSINESS WIRE)--Pernix Therapeutics Holdings, Inc. (NYSE Amex:PTX) announced today that its Board of Directors authorized the repurchase of up to $5,000,000 in shares of the Company's common stock.
"A strong cash position, debt-free balance sheet, and attractive levels of historical profitability instill the required confidence for the board of directors to approve this stock repurchase authorization," said Cooper Collins, President and Chief Executive Officer.
» Continue Reading Pernix Therapeutics Holdings, Inc. Announces Stock Repurchase Authorization
Pernix 1st Quarter Earnings Conference Call Invitation
Posted on 05/13/2010
MAGNOLIA, TEXAS – May 13, 2010 – Pernix Therapeutics Holdings, Inc (NYSE/AMEX: PTX), a specialty pharmaceutical company primarily focused on serving the needs of the pediatric marketplace, today announced it would report its financial results for the first quarter of 2010 on Monday, May 17th, 2010. The announcement will be followed by a conference call with the investment community scheduled to take place at 11:00AM ET Monday, May 17th.
» Continue Reading Pernix 1st Quarter Earnings Conference Call Invitation
Pernix Announces CEDAX® Acquisition
Posted on 03/24/2010
MAGNOLIA, Texas (March 24, 2010) – Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX) today announced the acquisition of the antibiotic CEDAX® (ceftibuten) from Shionogi Pharma, Inc.
CEDAX®, an oral third-generation cephalosporin, was originally discovered by Shionogi and Co., Ltd. and licensed to Schering-Plough. CEDAX® received marketing approval from the U.S. Food and Drug Administration in 1995. Indicated for mild to moderate acute bacterial exacerbations of chronic bronchitis, acute bacterial otitis media, pharyngitis and tonsillitis, the once-a-day medication was launched by Schering-Plough in 1996.
Pernix To Present At Cowen and Company Health Care Conference
Posted on 03/09/2010
MAGNOLIA, TX, March 9, 2010 -- Pernix Therapuetics Holdings, Inc. (NYSE Amex: PTX) (“the Company”) today announced that the Company will present at the Cowen and Company 30th Annual Health Care Conference at the Marriott Copley Place in Boston.
The Company’s presentation is scheduled for Wednesday, March 10, 2010 at 9:30 a.m. EST, and will be delivered by Cooper Collins, Chief Executive Officer of Pernix. An archived webcast, in addition to presentation slides, will be available on the Investor Relations page of the Pernix website at www.pernixtx.com.
» Continue Reading Pernix To Present At Cowen and Company Health Care Conference
Golf Trust Stockholders Approve Pernix Merger
Posted on 03/08/2010
Renamed Company To Trade On NYSE Amex Under Symbol "PTX"
CHARLESTON, SC, March 8, 2010 -- Golf Trust of America, Inc. ("GTA") (NYSE Amex: GTA) announced that GTA's stockholders voted to approve the four proposals that were conditions to closing the previously-announced merger between GTA and Pernix Therapeutics, Inc. (“Pernix”) at a Special Meeting of Stockholders held earlier today. Holders of approximately 78.2% of Golf Trust outstanding common shares voted in favor of the proposal to issue the merger shares, or 99.2% of total shares voted. The combined company will be renamed Pernix Therapeutics Holdings, Inc. We currently anticipate the merger will close on March 9, 2010 and that trading will commence on the NYSE Amex under the symbol "PTX" on March 10, 2010.
» Continue Reading Golf Trust Stockholders Approve Pernix Merger
Golf Trust and Pernix Announce Merger
Posted on 10/08/2009
Golf Trust of America, Inc. (“GTA”) (NYSE Amex: GTA) today announced an Agreement and Plan of Merger with Pernix Therapeutics, Inc., to create a publicly-traded specialty pharmaceutical company that the parties believe will be well-positioned for continued profitable growth as Pernix expands its geographic operations and product portfolio of commercially-established pediatric and other branded products. The transaction has been unanimously approved by the board of directors of both GTA and Pernix.